What is the role of Rashkind ductus occlusion device in the treatment of patent ductus arteriosus (PDA)?

Updated: Nov 20, 2018
  • Author: Luke K Kim, MD; Chief Editor: Stuart Berger, MD  more...
  • Print

The Rashkind ductus occlusion device consists of a 2-umbrella system delivered to the ductus in either the transvenous pathway or transarterial pathway. This therapy has a reported occlusion rate of 83%. Although used internationally, it is not approved for use in the United States.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!